Amylin

Christian Weyer, M.D. has been appointed senior vice president, R&D at Amylin Pharmaceuticals. Orville Kolterman, M.D., has been named senior vice president, chief medical officer. These changes are intended to strengthen Amylin’s focus on preparations for a new product launch and the advancement of its late-stage development programs, according to a company statement.

During his 10-year tenure at Amylin, Dr. Weyer has made valuable contributions to the business through leadership roles in the Research, Clinical, and Corporate Development organizations, most recently as vice president, Medical Development. In his new role, he will lead Amylin’s R&D organization, focusing on expanding opportunities with the company’s existing diabetes products, advancing the obesity and early diabetes pipeline, and driving research programs that support innovation and business growth.

Dr. Kolterman was previously senior vice president, R&D. In the newly created role of chief medical officer, he will work to strengthen Amylin’s ties with the medical community, policy-makers, patient advocacy groups, and other audiences that will be critical in supporting the successful launch of Bydureon and driving therapeutic innovation for patients. Dr. Kolterman will also continue to lead interactions with regulatory agencies and have responsibility for global safety activities.